Oriol Manuel

Oriol Manuel is identified as the lead author of a clinical review examining immunosuppression in Hepatitis C virus–infected kidney transplant recipients. His significance in the book is therefore intellectual and organizational rather than dramatic: he frames the post-transplant problem as a difficult management field in which kidney transplantation remains valuable despite inferior outcomes in HCV-positive recipients, while the immunosuppressive regimen must be adapted to risks that extend beyond the infection itself.

Identity and Clinical Context

Oriol Manuel is affiliated with the Transplantation Center and the Infectious Diseases Service at the University Hospital of Lausanne in Lausanne, Switzerland. He is also associated with the Division of Gastroenterology and Hepatology at that institution, placing his work at the intersection of transplantation, infectious disease, and liver medicine. The review is co-authored with Seema Baid-Agrawal, Darius Moradpour, and Manuel Pascual, and its subject is the management of immunosuppression after kidney transplantation in patients living with HCV infection.

The clinical setting he describes is one in which HCV infection is more prevalent among kidney transplant recipients than in the general population. Kidney transplantation remains the treatment of choice for most HCV-infected patients with end-stage kidney disease, even though both patient survival and graft survival are lower than in HCV-negative recipients. This contrast establishes the central tension of Manuel’s account: transplantation is still the preferred route out of advanced renal disease, but the post-transplant state creates conditions in which viral infection, liver injury, immunosuppression, and graft outcomes may interact adversely.

Argument About Immunosuppression

Manuel’s review treats immunosuppression as a possible determinant of HCV replication and disease after transplantation, but it does not reduce the problem to a single universally harmful drug or regimen. The evidence is presented as insufficient for a definitive strategy, and the best immunosuppressive approach remains challenging to determine. Rather than prescribing an inflexible protocol, the review argues that treatment should be individualized according to clinical parameters beyond HCV status, particularly the patient’s immunological risk and other comorbidities.

Induction therapy is not considered contraindicated in HCV-infected kidney transplant recipients. Manuel’s account allows that a short course of induction may actually be beneficial, resisting the assumption that HCV infection automatically requires avoidance of induction. At the same time, the review does not turn this possibility into a general rule; the unresolved evidence keeps induction within a broader, individualized assessment of transplant risk.

Corticosteroid withdrawal is presented as an acceptable option for selected patients, especially those with comorbidities such as diabetes mellitus or osteoporosis. This qualification is important because it shifts the decision away from HCV alone and toward the total burden of immunosuppression and coexisting disease. The choice to withdraw corticosteroids is therefore depicted as conditional, not routine, and dependent on the particular clinical profile of the recipient.

The review also leaves open the question of which calcineurin inhibitor is preferable. Large controlled trials addressing this issue are lacking, so the available evidence cannot establish a definitive best agent for HCV-infected recipients. Manuel’s position is consequently marked by disciplined uncertainty: the field has plausible strategies and recurring clinical patterns, but not enough controlled evidence to support a single optimal regimen.

Relation to Infection, Rejection, and Treatment

Manuel’s discussion belongs to a larger treatment sequence in which the timing of HCV eradication matters. Active chronic infection is distinguished from resolved infection through the combined interpretation of anti-HCV antibodies and HCV RNA: antibody positivity alone does not establish ongoing infection, whereas chronic infection requires both anti-HCV and detectable HCV RNA. Assessment must also determine the hepatic and extrahepatic impact of infection, using liver biopsy or noninvasive evaluations such as FibroScan to stage fibrosis and identify complications.

The broader transplant evidence gives particular weight to treating HCV before transplantation whenever possible. Patients with active infection require assessment of liver injury, and liver biopsy remains the most reliable method for determining the extent of fibrosis in kidney transplant candidates. Established or decompensated cirrhosis may require referral for simultaneous liver-kidney transplantation rather than kidney transplantation alone. Pretransplant viral clearance may also reduce the risk of post-transplant diabetes mellitus and immune complex-mediated glomerular disease, although its effect on later liver-injury progression is less certain.

Post-transplant interferon therapy is especially problematic because it has been associated with an increased risk of renal allograft rejection. That concern helps explain why attempts to eradicate HCV are generally directed toward the pretransplant period. The same therapeutic landscape is constrained by interferon toxicity: flu-like symptoms, anemia, neutropenia, depression, and anxiety can lead to dose reduction in 35–42% of patients and treatment discontinuation in about 30%. Manuel’s framework thus places immunosuppression within a chain of competing hazards rather than treating it as an isolated pharmacological choice.

Transplantation Amid Scarcity and Risk

The book’s discussion of HCV-positive donor kidneys adds a resource-allocation dimension to the clinical problem associated with Manuel’s work. HCV can be transmitted through organ transplantation, and kidneys from HCV-positive donors have therefore remained controversial, with wide variation among transplant centers and, in some jurisdictions, technical or legal restrictions. Yet the shortage of donated kidneys means that refusing such organs may lengthen the time patients remain on dialysis, even when transplantation with an HCV-positive kidney could offer a more favorable course than continued dialysis for some HCV RNA-positive candidates who cannot receive, decline, fail, or discontinue antiviral therapy.

This dilemma reinforces Manuel’s refusal of one-size-fits-all reasoning. A recipient’s HCV status, liver condition, immunological risk, comorbidities, access to antiviral therapy, and expected waiting time all shape the balance of benefit and harm. The wider evidence notes that HCV-positive kidneys were 2.60 times more likely to be discarded than HCV-negative kidneys, while transplantation of an HCV-positive kidney to an HCV-positive recipient could reduce time on the waiting list. The clinical decision therefore links individual immunosuppression to the institutional organization of scarcity.

Narrative Role and Significance

Oriol Manuel functions in the book as a synthesizing medical authority rather than as a character in a plotted narrative. His chapter gathers the competing pressures surrounding HCV after kidney transplantation and converts them into a principle of calibrated judgment: induction is not automatically forbidden, corticosteroid withdrawal may suit selected comorbid patients, the optimal calcineurin inhibitor is unsettled, and immunosuppressive regimens must be individualized.

His defining quality is methodological caution. The review acknowledges that HCV infection affects survival and that immunosuppression may influence viral replication or disease, but it also recognizes the absence of sufficiently large prospective controlled studies. Its conclusion is therefore not a dramatic resolution but a research demand: prospective controlled investigations are needed to determine the optimal immunosuppressive regimen for HCV-infected kidney transplant recipients. Manuel’s importance lies in making that uncertainty clinically legible without allowing it to erase the continuing value of transplantation.